FDA Clearance Tracker · P170013-S009
Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr. X
Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jun 28, 2022
Approved
Time to decision
18 days
Received Jun 10, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170013-S009
- Device name
- Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr. X
- Applicant
- MicroVention, Inc.
- Applicant location
- Aliso Viejo, CA
- Received
- Jun 10, 2022
- Decided
- Jun 28, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P170013
Device type
- Device type
- Intracranial coil-assist stent (QCA)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval to place the post-approval study titled LVIS X PAS on hold, because the sponsor does not intend to market the LVIS X and LVIS Jr. X devices in the United States at this time.
Source documents
Other decisions for MicroVention, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254035 · Decided Sep 3, 2026 · 261 days after receipt
Device type: Aspiration Thrombectomy Catheter (QEZ) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.